Strange Disease in Nigeria: Killed 17 Children in Lagos

LAGOS State government yesterday confirmed that a yet to be identified type of disease has claimed 17 lives while no fewer than 34 others are currently under close monitoring in Otodo Gbame community in Eti-Osa area of the state.

Those killed in the last couple of days are children that are between eight months and six years old.

State Commissioner for Health, Dr. Jide Idris told journalists yesterday that the cause and source of the “strange” disease were yet to be identified, though laboratory investigations were ongoing.

Idris said while there were several claims on possible cause, including measles, none of their preliminary findings have corroborated the claims, except for poor environment and slum condition of the community.

“The disease causing the outbreak is yet to be confirmed. However, the signs and symptoms are suggestive of Febrile Rash Illnesses (FRI). Blood samples (and throat swabs) from the patients and water samples from the community have been taken to the Virology Reference Laboratory at LUTH and Lagos State Drug Quality Control Laboratory (DQCL), LASUTH, Ikeja respectively. The source of the infection is still under investigation,” Idris said.

He explained that since February 9 when the health ministry was first notified of the outbreak, 47 sick cases have been confirmed in a house-to-house investigation, with 34 cases line-listed so far for monitoring.

“Seventeen dead patients have been identified with nine males and eight females. All are within the age range of eight to 72 months.”

The commissioner also informed that the first death occurred on January 6, 2016, “but the community would not alert the health authorities of the outbreak on time”.

Otodo Gbame community is an expansive, sandy riverine, flood prone and camp-lie settlements with an estimated population of 100, 000 people.

The people are mainly Egun though there are other tribes in the minority. The community is a slum with waste deposited at different spots. There are many scattered shallow wells in the community.

“The water from the wells is used mostly for bathing, washing and cooking. Majority of the residents claimed it is not used for drinking but a few said they sometimes drink from the well. The community head, Chief Hunpe Dansu confirmed the outbreak of the Febrile Rash Illnesses,” Idris noted.

On the management of line-listed cases, Idris said: “Seven cases were already followed up as at February 15, 2016. Six had recovered while one who was still ill was immediately taken to the Primary Health Centre (PHC) at Ikate for further medical attention.”

He added that other efforts were on to conduct comprehensive supplemental immunisation for all childhood preventable diseases in the community.

He urged the Lagos residents to practice health promotion and disease prevention measures like basic environmental sanitation, including proper disposal of refuse, avoiding open defecation and so on.

Excerpt: Guardian news

Lassar fever: 78 dead, 20 states affected – Health Minister

The Minister of Health, Prof. Isaac Adewole, on Thursday said 78 persons have so far died of Lassa fever since its return late last year.
Adewole, in a position paper on the wide spreading Zika fever, said Lassa fever has so far spread to 20 states of the country.
While assuring Nigerians that the government was capable of checking the spread of Zika fever to Nigeria, the Minister of Health said the outbreak of Lassa fever was under control.
He said: “It is important that I inform the nation that this current outbreak is under control as evidenced by decline in new suspected cases, new laboratory confirmed cases and newly reported cases by week.”
Adewole however said despite this achievement however, it will be dangerous to become complacent in dealing with the outbreak at this stage.
He said this is because the country could record another flare-up and a second wave deep in the dry season.
Following this, he said he has instructed the NCDC to work closely with the Lassa Fever Eradication Committee and other partners to develop a Lassa Fever Control Strategy that will withstand the test of time.
Adewole said it becomes worrisome that while Nigeria was still battling Lassa fever, Zika virus reared its head.
He, however, said the government was working assiduously to ensure Nigeria is not affected.

Among other measures, the Federal Government advised Nigerians, especially pregnant women, not to travel to the zones where the disease is prevalent.

It also said where this is impossible, travellers should protect themselves from mosquito bites.
Other measures include testing of Nigerians returning from the countries where Zika has taken root now, setting up of control agencies and enlightenment campaigns among others.
Below is the full text of the statement released on Thursday by Adewole:
You will all recall that on the 8th of January, 2016 I briefed the nation on the Lassa Fever outbreak that started in December, 2015 and which has now affected 20 States of the Federation. As at today the 10th of February 2016 Nigeria has recorded 176 cases with 108 deaths given a case fatality rate of 61.4%. Out of this 78 are confirmed cases and 49 deaths given a specific case fatality rate of 62.8%.
The total cases reported (suspected, probable and confirmed): 176; Total deaths (suspected, probable and confirmed):  108 (CFR: 61.4%). Total confirmed cases: 78; Deaths in confirmed cases: 49 (CFR: 62.8%). As at today, 20 states are currently following up contacts, or have suspected or probable cases with laboratory results pending or laboratory confirmed cases.
It is important that I inform the nation that this current outbreak is under control as evidenced by decline in new suspected cases, new laboratory confirmed cases and newly reported cases by week.
Despite this achievement however, you will agree with me that it will be dangerous if we go complacent at this stage, as we could record another flare-up and a second wave deep in the dry season. I have instructed the NCDC to work closely with the Lassa Fever Eradication Committee and other partners to develop a Lassa Fever Control strategy that will withstand the test of time.
As we were fighting to interrupt the transmission of Lassa fever in our country, another health emergency of international health concern broke out in the Americas and have been spreading fast.
In late 2014, Brazil detected a cluster of febrile rash illness related to Zika virus in its Northeast region (Bahia) that was subsequently associated with the Zika virus in April 2015. The outbreak spread widely to other parts of Brazil and other countries and by February 2016, Zika viral transmission has been documented in a total of 44 countries and territories). This includes 2 African countries of Cape Verde and Gabon that reported transmission in between 2015 and 2016.

As of today Brazil and Columbia have been the most affected countries with an estimated cases ranging between 600,000 and 1,700,000.

Zika Virus belongs to the flavivirus group of viruses to which Yellow fever and Dengue viruses also belong. It was first discovered in Zika forest in Uganda in the year 1947. It is transmitted to people primarily through the bite of infected mosquitoes of Aedes species among which are Aedes aegypti, Aedes Luteocephalus and A. albopictus. These are the same mosquitoes that spread yellow fever, dengue and chikungunya fevers. These mosquitoes exist in Nigeria and with the exception of Aedes albopictus, have been found to be transmitting yellow fever and dengue viruses. Unlike the Anopheles mosquitoes that spread malaria, these group of mosquitoes are active during the, fly and bite mostly during day time and early evenings. The spread of Zika virus to countries within the geographical zone of the disease vectors of the Aedes mosquitoes is therefore most likely. These mosquitoes typically lay eggs in and near standing water in things like buckets, bamboo holes, bowls, animal dishes, flower pots, discarded plastic bags and vases.  They prefer to bite people, and live indoors and outdoors near people.
Nigerian scientists working in Western Nigeria in 1954 discovered Zika virus in Nigeria. Further studies in the years 1975 to 1979 showed that 40% of Nigeria adults and 25% of Nigerian children have antibodies to Zika virus, meaning they are protected against this virus.
It is important however, to state categorically, that until now in Africa and Nigeria inclusive, this virus does not cause any serious illness and those so far infected individually recover fully with no serious complications
Arrival of this virus in some countries of the Americas, notably Brazil, has however changed this and its circulation is now associated with a steep increase in the birth of babies with abnormally small heads named scientifically as Microcephalia. It is also associated with increase in cases of Guillain-Barré syndrome (GBS), a poorly understood condition in which the immune system attacks the nervous system, sometimes resulting in paralysis. The clinical presentation of Zika is similar to many other tropical diseases such as Malaria, typhoid fever common cold or another mosquito-borne disease. This usually makes its diagnosis often difficult.
Although two African countries have reported Zika infection in the recent outbreak and in the past, many others, causal relationship between Zika virus infection, birth defects and neurological syndromes has not been established in this continent.
There is as of now, no known specific treatment for Zika virus disease. Treatment is therefore generally supportive and it include rest, fluids, and use of pain killers and antipyretics. In a pregnant woman with laboratory evidence of Zika virus in serum or amniotic fluid, serial ultrasounds should be considered to monitor fetal anatomy and growth every 3–4 weeks. Referral to a maternal-fetal medicine or infectious disease specialist with expertise in pregnancy management is recommended.
Despite the fact that some Nigerians are immune to the Zika virus infection as demonstrated by previous studies, it is important and advisable that Nigerians should be careful and protect themselves from mosquito bites.
There is no vaccine for Zika virus, and no cure other than rest, plenty of fluids and perhaps over-the-counter medication to reduce fevers, aches and pains as previously mentioned. This therefore means that prevention is most effective means of preventing transmission.
I advise all Nigerians, particularly pregnant women to avoid travelling to countries infected by this virus in these periods. If however, you are to visit any country where Zika virus is now being actively transmitted, you are advised to  protect yourselves from mosquito bites. Pregnant women considering travel to affected areas may wish to consult their health-care provider prior to travel and after return. They should also practice personal and household steps to prevent mosquito, including putting mosquito repellant on their clothes and skin, wear long sleeves and pants, and sleep underneath mosquito nets at night, where possible. I wish to call on all Nigerians to support our pregnant women and help them access anti-mosquito repellants.
All States of the Federation are hereby advised to immediately embark on health education campaigns to empower communities take actions to protect themselves from Zika Virus as well as other mosquito-borne diseases.
Nigerians returning from these countries should report themselves to any nearest health centres if they start to feel any sickness that requires care, and such a person should inform the healthcare workers about their travel history. I have instructed the Port Health Services of my Ministry to immediately adjust and include points of entry screening to capture anti-Zika activities.
The Federal Ministry of Health shall collaborate with Ministry of Environment to embark immediately on mosquito population reducing campaigns that will include the use of larvicide (insecticide that kills the mosquito in its larval stage).
The NCDC has been directed to enhance Zika virus surveillance activities and work with the Arbovirus Research Centre, Enugu to embark on extensive vector control and research activities to confirm the current circulation status of both Zika virus and the mosquitoes that spread it.
The NCDC has activated EOC on Zika to specifically focus on transmission to track Zika virus in communities and in mosquitoes.
Healthcare workers are to report any illness in pregnant women with symptoms similar to any haemorrhagic fever, any birth defects, particularly microcephaly to the State Epidemiologists and the NCDC.
The NCDC is to expand the Field Epidemiology Training program, laboratory testing, health care provider training, and vector surveillance and control in at risk areas for Zika virus transmission. All laboratories currently testing for other haemorrhagic fever viruses should include testing for Zika virus also.
Furthermore, I wish to call on all our partners to support our efforts at preventing this new scourge from entering our country.
Finally, I wish to once again call on Nigerians to remain calm and remain vigilant and report any suspected case of an acute febrile illness in pregnant women in particular, to any nearest health facility.
The public is also called to maintain good individual and “community hygiene” to discourage creation of mosquito breeding grounds near homes and nearby surrounding. All States are called upon to commence anti-mosquito campaign including engaging the services of sanitary inspectors with their appropriate deployment.
All health facilities in the country are hereby directed to emphasize routine infection prevention and control measures and ensure all pregnant women recive special attention and are treated free, in case of presentation with symptoms similar to any viral haemorrhagic fever.
As you may all be aware, I commissioned a novel call-in centre established within the NCDC with specific centre call-in number for handling epidemics and health emergencies. Any suspected case can be referred to this centre via these numbers: 097000010-19. This centre shall also provide the NCDC the opportunity for improved coordination with the various States, the FCT and our partners.
The Lassa Alert system just established is also been deployed to operate the Zika prevention activities throughout the year. All Polio EOC Centres are also directed to activate all their surveillance system in the country to compliment NCDC activity.
The Federal Ministry of Health, with full cooperation and involvement of our partners and the private sector, shall mobilise all resources to ensure enhanced readiness and effective prevention and control measures. I therefore seek for your full cooperation in this fight to see that we keep you all safe and healthy.
God bless the Federal Republic of Nigeria.
Excerpt: theeagleonline

SYMPTOMES AND CURE FOR LEIOMYOMA

Leiomyomas of the uterus are one of the most common pathologic abnormalities of the female genital tract. Their occurrence increases with age, and they are found in 20–50% of women older than 30 years. Although found elsewhere in the body, leiomyomas most frequently occur in the myometrium. Uterine leiomyomas are commonly referred to as myomas, fibromyomas, or “fibroids” because of their firm, fibrous character and high content of collagen.

Leiomyomas of the uterus are the most common indication for hysterectomy in the United States. Approximately 175,000 hysterectomies are performed annually for leiomyomas. Uterine leiomyomas result in masses associated with a variety of gynecologic problems, the most prominent of which are the asymptomatic pelvic mass or abnormal vaginal bleeding.

The last two decades have seen rapid advancements in the diagnosis and treatment of uterine leiomyomas. The introduction of pelvic ultrasonography sonohysterography, hysteroscopy, and magnetic resonance imaging (MRI) have made it possible to detect small myomas not clinically suspected as a cause of abnormal bleeding. It is also possible to make a definitive diagnosis of a pelvic mass as a uterine myoma short of performing laparotomy or laparoscopy. Understanding the relation of sex steroid hormones and uterine leiomyomas has provided the foundation for using gonadatropin-releasing agonists (GnRH), which have facilitated treatment of leiomyomas by hysteroscopy, laparoscopy, and the liberal use of vaginal hysterectomy. With the introduction of the antiprogesterone RU486 and other drugs that can be used in lieu of surgery, the 21st century will be marked by dramatically new treatments of leiomyomas of the uterus.

SYMPTOMS

Uterine myomas are common, most are asymptomatic and require no treatment. Predominantly intramural or subserous, they are typically found in the highly screened U.S. population as unsuspected pelvic masses at the time of an annual examination and Pap smear.

Patients are usually between 30 and 50 years old. In the past, indications for intervention for asymptomatic uterine leiomyomas included uterine size, inaccessible ovaries, facilitation of estrogen replacement, and a rapid change in uterine size. A review of the literature does not support surgical intervention for uterine leiomyomas based on size alone. According to Mayer and Shipilov, normal ovaries that are not identified by ultrasonography can be differentiated from uterine leiomyomas on MRI, allowing exclusion of ovarian tumors.7 The addition of hormone replacement therapy in standard doses does not appear to provide sufficient amounts of estrogen or progesterone to cause uterine growth. Even the age-old accepted theory of a “rapidly enlarging uterus” has been challenged as an indication for intervention for the asymptomatic leiomyoma. Parker and coworkers reviewed the medical records of 1332 women admitted between 1988 and 1992 for surgical management of uterine leiomyomas. They found no correlation between rapid uterine growth and uterine sarcoma.8

Common symptoms associated with leiomyomas are menorrhagia, pelvic pressure or pain, and reproductive symptoms. The most common symptom associated with leiomyomas is menorrhagia. The cause of leiomyoma-associated menorrhagia is unknown. Ulceration of a submucous myoma and compression of venous plexus or adjacent myometrium and endometrium by intramural myoma have been postulated.9 Rarely, fibroids may present as a result of pressure on neighboring organs, such as urinary frequency or urinary obstruction secondary to urethral obstruction. Rectal symptoms also are rare, but blockage or irritation of the rectum and rectal sigmoid can occur. Acute pain associated with a low-grade fever and uterine tenderness may be observed with degeneration of leiomyomas or with torsion or a pedunculated subserous myoma.

The major clinical issues involved with leiomyomas of the uterus include the differential diagnosis, management of the asymptomatic pelvic mass, and appraisal of the role of the fibroid in various clinical problems such as abnormal bleeding, pain, infertility, and pregnancy. A review of current approaches to the differential diagnosis and treatment options for leiomyomas is appropriate.

TREATMENT

The problems associated with bleeding myomas are related primarily to anemia, but the myomas can also create difficulties in maintaining an acceptable lifestyle because of the problems of pelvic discomfort. The submucous myoma particularly can be the cause of major hemorrhage and produce emergency situations. Intramural fibroids and a distorted endometrial cavity can produce a similar picture and force intervention.

The clinical problems produced by the mass of the myomatous uterus usually are not observed until the mass rises out of the pelvis. In nonpregnant states, the mass may cause ureteral obstruction, bladder and rectal pressure, pelvic pain, and if the mass extends to the umbilicus or above, diaphragmatic pressure. Rarely, when the pedunculated subserous myomas twist and causes acute or chronic symptoms or marked abdominal protuberance, surgical intervention is warranted.

Benign degeneration of the myoma is usually caused by avascular necrosis. It is principally seen during pregnancy, when it should be treated symptomatically. Malignant degeneration results in sarcoma, which occurs in 0% to 5% of cases. Sarcomas arising de novo in normal uteri usually tend to be more aggressive. Changes in size, especially those associated with vaginal bleeding a postmenopausal woman, are signs of possible malignant degeneration.

Major advances in the treatment of symptomatic fibroids have created treatment options. The principal treatments for uterine myomas are control of the symptoms after a benign diagnosis is established. The options for treatment of symptomatic fibroids are medical management and surgery.

Medical Management

The management of symptomatic uterine myomas has traditionally involved surgery. However, the introduction of GnRH agonists in the 1980s offered temporary relief to women with myomas who do not desire surgery and are approaching menopause.18

The use of a GnRH agonist produces a hypoestrogenic state, which leads to a median reduction in uterine volume of approximately 50%. The maximal effect is seen after 12 weeks of therapy, with no further reduction in uterine size observed between 12 and 24 weeks of therapy. Unfortunately, rapid regrowth of myomas after therapy and side effects related to the hypoestrogenic state such as bone loss and hot flashes have limited the usefulness of the GnRH agonists.

To overcome the side effects of long-term GnRH therapy and maintain decrease in uterine size, Friedman and coworkers proposed an “add-back” regimen of estrogen and progesterone in small doses.19 Early reports with add-back therapy appear promising, but the high cost ($300.00/month) associated with GnRH agonist with estrogen and progesterone have limited this approach. The ultimate place for GnRH agonist therapy may be as a presurgical treatment before myomectomy or hysterectomy.

The GnRH agonist can cause a cessation of menses, allowing severe anemia to be corrected before surgery and avoiding preoperative blood transfusions. It also been shown to reduce operative blood lose. Preoperative GnRH also opens the possibility for converting some cases of abdominal hysterectomy into a vaginal hysterectomy through reduction in uterine mass.

Surgical Management

The key factors governing the surgical options are the patient's age, fertility status, and reliability; the impact of fibroids on surrounding organs; and attendant medical, surgical, or anesthetic risks that may complicate surgical treatment. If fertility is a consideration and the patient has major symptoms, myomectomy is the procedure of choice. Myomectomy should be preceded by a hysterosalpingogram to determine the location and patency of the fallopian tubes and to screen for submucous myomas. Extensive and aggressive myomectomy runs the risk of resulting in emergency hysterectomy. The use of uterine tourniquets and vasopressin has reduced the amount of blood loss during myomectomy. Dillon reported that, with the use of vasopressin, 72% of patients undergoing myomectomy did not need blood products.20 Other complications associated with abdominal myomectomy are pelvic adhesion and bowel obstruction. In comparing the overall morbidity associated with myomectomy with that of hysterectomy, Iverson found no difference.21

A patient undergoing myomectomy should understand that the procedure is a treatment for fibroids, not a cure. There is a 15% recurrence rate of myomas after myomectomy and a 10% reoperation rate.

Dubuisson first reported myomectomy under laparoscopic control.22 Technical innovations such as electric morsulators (Karl Stortz) and simplified suturing techniques have made this procedure more feasible. Laparoscopic myomectomy can be offered as an alternative to abdominal myomectomy in selected cases (i.e. with a single myoma smaller than 6 cm) and should only be attempted by experienced laparoscopic surgeons. It has been suggested that adequate closure of the myometrium after laparoscopic myomectomy is difficult and may account for uterine rupture during pregnancy after undergoing a laparoscopic myomectomy.

UN warns against laws restricting pregnancy

The UN High Commissioner for Human Rights, Zeid Al Hussein, disclosed this in a statement made available to newsmen on Friday in New York.

• Published: 13.49
• Pulse News Agency Local By NAN

• Print
• eMail

The United Nations (UN) has called for the repeal of laws and policies that restrict access to sexual and reproductive health services in contravention of international standards.

The UN High Commissioner for Human Rights, Zeid Al Hussein, disclosed this in a statement made available to newsmen on Friday in New York.

The statement said that the UN position was in response to advice to women by some governments to delay getting pregnant due to the possible link between the rampaging Zika virus and neurological disorders affecting newborns.

According to the statement, upholding women’s human rights was essential if the response to the Zika health emergency would be effective.

``Clearly, managing the spread of Zika is a major challenge to governments in Latin America.

``However, the advice of some governments to women to delay getting pregnant ignores the reality that many women and girls simply cannot exercise control over when they become pregnant.

``The circumstance is made more difficult in environment where sexual violence is so common,’’ the statement said.

The statement noted that ``in situations where sexual violence is rampant and sexual and reproductive health services are unavailable, efforts to halt Zika crisis will not be enhanced by stopping women from getting pregnant’’.

The statement stressed that, amid the continuing spread of the virus, authorities must ensure that their public health responses were pursued in conformity with human health-related rights obligations.

``Upholding human rights is essential to an effective public health response.

``This requires that governments ensure that women, men and adolescents have access to comprehensive and affordable quality sexual and reproductive health services and information, without discrimination.

``Health services must be delivered in a way that ensures the woman’s informed consent, respect for her dignity and the guarantee of her privacy.

``Laws and policies that restrict her access to these services must be urgently reviewed in line with human rights obligations in order to ensure the right to health for all in practice,’’ it stated.

The News Agency of Nigeria (NAN) reports that the World Health Organisation (WHO) has declared a public health emergency on the spread of the virus.

The Organisation had said that causative link between Zika and microcephaly - babies born with abnormally small heads and underdeveloped brain- and Guillain-Barré Syndrome (a neurological condition), is still under investigation.

101 Die From Lassa Fever In Nigeria, Says NCDC

The Nigeria Centre for Disease Control (NCDC) has disclosed that the growing Lassa Fever outbreak in Nigeria has killed a total of 101 people.

Statistics from NCDC show that reported cases of the haemorrhagic disease — both confirmed and suspected — stand at 175 with a total of 101 deaths since August.

According to the NCDC, deaths from the virus were recorded in Abuja, Lagos, and 14 other states.

The outbreak of Lassa Fever was only announced in January, months after the first case of the disease happened in August, with subsequent deaths reported in 10 states, including Abuja.

In 2015, 12 people died in Nigeria out of 375 infected, while in 2012 there were 1,723 cases and 112 deaths, according to the NCDC.

In neighbouring Benin Republic, at least nine people have died in a Lassa outbreak, with a total of 20 suspected cases.

ZIKA VIRUS: Prevention!

    No vaccine exists to prevent Zika virus disease (Zika).
    Prevent Zika by avoiding mosquito bites (see below).
    Mosquitoes that spread Zika virus bite mostly during the daytime.
    Mosquitoes that spread Zika virus also spread dengue and chikungunya viruses.

When traveling to countries where Zika virus or other viruses spread by mosquitoes are found, take the following steps:


    Wear long-sleeved shirts and long pants.
    Stay in places with air conditioning or that use window and door screens to keep mosquitoes outside.
    Sleep under a mosquito bed net if you are overseas or outside and are not able to protect yourself from mosquito bites.
    Use Environmental Protection Agency (EPA)-registered insect repellents. All EPA-registered insect repellents are evaluated for effectiveness.
        Always follow the product label instructions
        Reapply insect repellent as directed.
        Do not spray repellent on the skin under clothing.
        If you are also using sunscreen, apply sunscreen before applying insect repellent.
    If you have a baby or child:
        Do not use insect repellent on babies younger than 2 months of age.
        Dress your child in clothing that covers arms and legs, or
        Cover crib, stroller, and baby carrier with mosquito netting.
        Do not apply insect repellent onto a child’s hands, eyes, mouth, and cut or irritated skin.
        Adults: Spray insect repellent onto your hands and then apply to a child’s face.
    Treat clothing and gear with permethrin or purchase permethrin-treated items.
        Treated clothing remains protective after multiple washings. See product information to learn how long the protection will last.
        If treating items yourself, follow the product instructions carefully.
        Do NOT use permethrin products directly on skin. They are intended to treat clothing.

Sick with Chikungunya, Dengue, or Zika? Protect yourself and others from mosquito bites during the first week of illness.

If you have Zika, protect others from getting sick

    During the first week of infection, Zika virus can be found in the blood and passed from an infected person to another mosquito through mosquito bites. An infected mosquito can then spread the virus to other people.
    To help prevent others from getting sick, avoid mosquito bites during the first week of illness.

Another Big One-ZIKA VIRUS

Zika virus (ZIKV) is a member of the Flaviviridae virus family and the Flavivirus genus, transmitted by daytime-active Aedes mosquitoes, such as A. aegypti.


In humans, the virus causes a mild illness known as Zika fever, Zika, or Zika disease, which since the 1950s has been known to occur within a narrow equatorial belt from Africa to Asia. In 2014, the virus spread eastward across the Pacific Ocean to French Polynesia, then to Easter Island and in 2015 to Mexico, Central America, the Caribbean, and South America, where the Zika outbreak has reached pandemic levels.

Transmission

 Zika virus is transmitted by daytime-active mosquitoes and has been isolated from a number of species in the genus Aedes, such as A. aegypti, and arboreal mosquitoes such as A. africanus, A. apicoargenteus, A. furcifer, A. hensilli, A. luteocephalus and A. vitattus. Studies show that the extrinsic incubation period in mosquitoes is about 10 days. Zika virus can migrate between humans through sexual contact and it can also cross the placenta, affecting an unborn fetus. A mother already infected with Zika virus near the time of delivery can pass on the virus to her newborn around the time of birth, but this is rare.
The vertebrate hosts of the virus are primarily monkeys and humans. Before the current pandemic, which began in 2007, Zika virus "rarely caused recognized 'spillover' infections in humans, even in highly enzootic areas".

symptoms 

Common symptoms of infection with the virus include mild headaches, maculopapular rash, fever, malaise, conjunctivitis, and joint pains. The first well-documented case of Zika virus was described in 1964; it began with a mild headache, and progressed to a maculopapular rash, fever, and back pain. Within two days, the rash started fading, and within three days, the fever resolved and only the rash remained. Thus far, Zika fever has been a relatively mild disease of limited scope, with only one in five persons developing symptoms, with no fatalities, but its true potential as a viral agent of disease is unknown.

As of 2016, no vaccine or preventative drug is available. Symptoms can be treated with rest, fluids, and paracetamol (acetaminophen), while aspirin and other nonsteroidal anti-inflammatory drugs should be used only when dengue has been ruled out to reduce the risk of bleeding.

Excerpt from wikipedia and BBC(https://en.wikipedia.org/wiki/Zika_virus )